J B Chemicals and Pharmaceuticals Ltd banner

J B Chemicals and Pharmaceuticals Ltd
NSE:JBCHEPHARM

Watchlist Manager
J B Chemicals and Pharmaceuticals Ltd Logo
J B Chemicals and Pharmaceuticals Ltd
NSE:JBCHEPHARM
Watchlist
Price: 2 012.9 INR 1.77% Market Closed
Market Cap: ₹323.2B

EV/EBITDA

27.8
Current
5%
More Expensive
vs 3-y average of 26.5

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
27.8
=
Enterprise Value
₹317.7B
/
EBITDA
₹11.3B

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
27.8
=
Enterprise Value
₹317.7B
/
EBITDA
₹11.3B

Valuation Scenarios

J B Chemicals and Pharmaceuticals Ltd is trading above its 3-year average

If EV/EBITDA returns to its 3-Year Average (26.5), the stock would be worth ₹1 914.19 (5% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-37%
Maximum Upside
No Upside Scenarios
Average Downside
20%
Scenario EV/EBITDA Value Implied Price Upside/Downside
Current Multiple 27.8 ₹2 012.9
0%
3-Year Average 26.5 ₹1 914.19
-5%
5-Year Average 23.3 ₹1 685.52
-16%
Industry Average 21.2 ₹1 530.58
-24%
Country Average 17.7 ₹1 277.35
-37%

Forward EV/EBITDA
Today’s price vs future ebitda

Today's Enterprise Value EBITDA Forward EV/EBITDA
₹317.7B
/
Jan 2026
₹11.3B
=
27.8
Current
₹317.7B
/
Mar 2026
₹12B
=
26.6
Forward
₹317.7B
/
Mar 2027
₹13.8B
=
23
Forward
₹317.7B
/
Mar 2028
₹16.6B
=
19.2
Forward

Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.

Peer Comparison

All Multiples
EV/EBITDA
P/E
All Countries
Close
Market Cap EV/EBITDA P/E
IN
J B Chemicals and Pharmaceuticals Ltd
NSE:JBCHEPHARM
309.7B INR 27.8 41.6
US
Eli Lilly and Co
NYSE:LLY
867B USD 28.4 42
US
Johnson & Johnson
NYSE:JNJ
555.4B USD 16.9 26.4
CH
Roche Holding AG
SIX:ROG
248.4B CHF 11.5 19.3
UK
AstraZeneca PLC
LSE:AZN
224.8B GBP 16.1 29.1
CH
Novartis AG
SIX:NOVN
221.8B CHF 12.4 20
US
Merck & Co Inc
NYSE:MRK
283.6B USD 9.7 15.5
IE
Endo International PLC
LSE:0Y5F
244.4B USD 386.8 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 7.9 10.7
US
Pfizer Inc
NYSE:PFE
152.4B USD 7.5 19.5
US
Bristol-Myers Squibb Co
NYSE:BMY
118.8B USD 7.1 16.9
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
J B Chemicals and Pharmaceuticals Ltd
NSE:JBCHEPHARM
Average EV/EBITDA: 48.4
27.8
17%
1.6
US
Eli Lilly and Co
NYSE:LLY
28.4
21%
1.4
US
Johnson & Johnson
NYSE:JNJ
16.9
8%
2.1
CH
Roche Holding AG
SIX:ROG
11.5
6%
1.9
UK
AstraZeneca PLC
LSE:AZN
16.1
12%
1.3
CH
Novartis AG
SIX:NOVN
12.4
5%
2.5
US
Merck & Co Inc
NYSE:MRK
9.7
4%
2.4
IE
E
Endo International PLC
LSE:0Y5F
386.8
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.9
2%
3.9
US
Pfizer Inc
NYSE:PFE
7.5
-8%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.1
-10%
N/A

Market Distribution

Higher than 70% of companies in India
Percentile
70th
Based on 2 785 companies
70th percentile
27.8
Low
0.4 — 11.9
Typical Range
11.9 — 27.8
High
27.8 —
Distribution Statistics
India
Min 0.4
30th Percentile 11.9
Median 17.7
70th Percentile 27.8
Max 47 834.4

J B Chemicals and Pharmaceuticals Ltd
Glance View

In the bustling marketplace of India's pharmaceutical industry, J B Chemicals and Pharmaceuticals Ltd. has carved its niche, a testament to its strategic vision and operational prowess. Founded in 1976 by Janak Mehta, the company has grown from its humble beginnings into a leading player in both the domestic and international arenas. Originally rooted in the ethos of quality and innovation, it established a firm foothold in the pharmaceutical sector through a diverse portfolio that includes formulations, active pharmaceutical ingredients (APIs), and contract manufacturing. As a vertically integrated company, J B Chemicals leverages its ability to control the manufacturing process from start to finish, ensuring strict quality measures and cost efficiencies, vital in tackling industry competition and regulatory challenges. The heart of J B Chemicals’ revenue model is its well-rounded product line that spans a range of therapeutic categories, including gastrointestinal, cardiovascular, and anticold segments. Blockbuster brands like Cilacar and Metrogyl have propelled the company to the top ranks within India, while its export division flourishes, contributing significantly to total earnings. With footprints in more than 30 countries, particularly in Russia and South Africa, the company taps into the growing demand for generic medicines worldwide. Moreover, by embracing innovation and investing in research and development, J B Chemicals continues to introduce new and improved medical solutions, positioning itself as a dynamic player in meeting global healthcare needs.

JBCHEPHARM Intrinsic Value
1 219.89 INR
Overvaluation 39%
Intrinsic Value
Price ₹2 012.9
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett